… for hospitalized patients in the US (22), and supported a recent trial demonstrating the
antiviral activity molnupiravir in volunteers with mild symptomatic COVID-19 (23), and the FDA …

… might encourage the use of molnupiravir in these patients despite the remaining controversy
in … analyzed 45 patients who were hospitalized for other reasons and used molnupiravir for …

… (n= 130) to find out the safety and dosing range of Molnupiravir. It was found safe and well
… which was a Phase Ib/IIa dose escalation study conducted in eighteen COVID-19 patients. …

… was reached, the dose escalation was discontinued [121]. … Molnupiravir was well tolerated
at all three doses without any … of 4 of patients receiving 300, 600 or 800 mg of molnupiravir, …

… patients with nonsevere COVID-19. Nirmatrelvir–ritonavir is probably more effective than
molnupiravir … Most trials were conducted with unvaccinated patients, before the emergence of …

… be recruited among patients who are prescribed molnupiravir for treatment of … dose
and safety of molnupiravir in patients with early SARS-CoV2: a Phase I, open-label, dose-escalating…

… Similar data were reported in a dose-escalating study, where doses ranging from 300 to 800
… Molnupiravir could be the drug of choice for patients with COVID-19 reporting comorbidities …

… In this investigation, the primary endpoint was the percentage of patients who were hospitalized
or died by day-29, and the treatment impact estimates for this endpoint were lower in all-…

… The nucleoside inhibitor molnupiravir received EUA shortly … was built during the dose
escalation based on the preliminary … Dosing for > 5 days in symptomatic patients was predicted to …

… duration that patients experience symptom day quality of life decrements. For patients who
… parameters were applied to estimate the risk of escalation of care (general ward, ICU, and …